Taf + Emtricitabine + Darunavir + Cobicistat Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Darunavir- 800 mg + Cobicistat-1 50 mg + Emtricitabine- 200 mg + TAF-10 mg
Reference Brands: Symtuza(Eu & US)
Category: Anti Viral
Symtuza is a once-daily, complete HIV-1 treatment with Darunavir, Cobicistat, Emtricitabine, and TAF. FDA and EMA approved, it offers high resistance protection and improved safety in a single-tablet regimen. TAF + Emtricitabine + Darunavir + Cobicistat is available in Tablet and strengths such as Darunavir- 800 mg + Cobicistat-1 50 mg + Emtricitabine- 200 mg + TAF-10 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, TAF + Emtricitabine + Darunavir + Cobicistat is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
TAF + Emtricitabine + Darunavir + Cobicistat can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Symtuza is the first once-daily, single-tablet regimen combining Darunavir 800 mg, Cobicistat 150 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 10 mg for the treatment of HIV-1 infection. Approved by both the FDA and EMA, Symtuza is indicated for adults and adolescents (≥12 years, ≥40 kg) who are treatment-naïve or virologically suppressed. The high resistance barrier of Darunavir, boosted by Cobicistat, makes Symtuza ideal for durable viral suppression. Its TAF backbone ensures better renal and bone safety than older TDF-based regimens. Symtuza offers the simplicity of a PI-based single-tablet regimen, enhancing long-term adherence.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
This combination is used for the treatment of HIV-1 infection. It works by suppressing viral replication, increasing CD4 cell counts, and helping achieve long-term viral suppression when used as part of antiretroviral therapy.
It is made from the active ingredients tenofovir alafenamide (TAF), emtricitabine, darunavir, and cobicistat. TAF and emtricitabine are nucleoside reverse transcriptase inhibitors, darunavir is a protease inhibitor, and cobicistat is a pharmacokinetic enhancer.
A known trade name for this four-drug fixed combination is Symtuza in the USA, EU, and UK.
Symtuza is manufactured by Janssen (Johnson & Johnson) in collaboration with Gilead Sciences.
The generic name is tenofovir alafenamide + emtricitabine + darunavir + cobicistat.
The main brand name is Symtuza.
It is manufactured by Janssen in the EU/USA, with production also handled through their authorized global manufacturing partners.
Related Products
Maraviroc
Strength:
150 mg, 300 mg, 20 mg
Form: Tablets / Oral solution
Reference Brands: Selzentry (USA), Celsentri (EU)
View Details
Raltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
